GenSight Biologics
Organization Description
GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases.
Related News
December 11, 2020
A team of researchers, including Dr. Patrick Yu-Wai-Man from the University of Cambridge and Dr. José-Alain Sahel from the University of Pittsburgh and Institut de la Vision, Paris, has successfully treated 37 participants suffering from Leber hereditary optic neuropathy (LHON). A landmark trial for mitochondrial gene therapy The results of this phase 3 clinical trial...
October 09, 2019
GenSight Biologics has recently released data showing the effectiveness of GS010, the company's gene therapy for Leber Hereditary Optic Neuropathy (LHON), a mitochondrial disease that can lead to blindness. Like in previous studies, this therapy had a bilateral effect. Gene Therapy In LHON, the mitochondrial protein ND4 is poorly expressed through mitochondrial DNA (mtDNA). GS010...
